Phio Pharmaceuticals Correlations
| PHIO Stock | USD 2.64 0.13 5.18% |
The current 90-days correlation between Phio Pharmaceuticals Corp and ZyVersa Therapeutics is 0.09 (i.e., Significant diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Phio Pharmaceuticals Correlation With Market
Average diversification
The correlation between Phio Pharmaceuticals Corp and DJI is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Phio Pharmaceuticals Corp and DJI in the same portfolio, assuming nothing else is changed.
Phio |
Moving together with Phio Stock
Moving against Phio Stock
| 0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.52 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.48 | VREX | Varex Imaging Corp | PairCorr |
| 0.4 | AGIO | Agios Pharm | PairCorr |
| 0.36 | AVTE | Aerovate Therapeutics | PairCorr |
| 0.33 | SGMO | Sangamo Therapeutics Buyout Trend | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Phio Stock performing well and Phio Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Phio Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 3.79 | (0.66) | 0.00 | (0.19) | 0.00 | 7.95 | 26.70 | |||
| APGN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| EFTR | 7.57 | (4.57) | 0.00 | (470.75) | 0.00 | 8.70 | 88.91 | |||
| IMMX | 4.25 | (0.12) | (0.02) | 0.01 | 4.55 | 9.38 | 32.68 | |||
| CNSP | 4.41 | (0.35) | 0.00 | (0.26) | 0.00 | 9.09 | 39.29 | |||
| ZVSA | 4.10 | (1.47) | 0.00 | (0.36) | 0.00 | 7.57 | 78.93 | |||
| VECT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AVRO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CWBR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| OCEA | 3.20 | (0.66) | 0.00 | (14.67) | 0.00 | 4.29 | 27.01 |
Phio Pharmaceuticals Corporate Management
| Jim Cardia | VP Operations | Profile | |
| Caitlin Kontulis | VP Secretary | Profile | |
| Dr MedSc | Interim Director | Profile | |
| Linda Mahoney | Senior Development | Profile |